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Purpose
To report the current state of adeno-associated virus
mediated retinal gene therapy for inherited retinal degen-
erations caused by the RPE65 gene, and its application to
auditory, renal and ocular ciliopathies.
Methods
In Phase I/II clinical trials, 12 subjects with confirmed
mutations in the RPE65 gene causing inherited retinal
degeneration were given a unilateral sub-retinal injection
of AAV.RPE65 into the worse seeing-eye. Objective and
subjective visual testing were performed at baseline and
following intervention. Subsequently, 11/12 subjects
received injections in the contralateral eye, in a Phase II
follow on study. These results have initiated the first Phase
III clinical trial for retinal disease. The methods and tech-
nology used in this study have enabled gene transfer to
cells involved with ciliopathies. Unilateral subretinal, intra-
otocyst, and retrograde ureteral injections of AAV vectors
were carried out in cohorts of mice. Intra-otocyst injec-
tions were carried out at embryonic day 12; ocular and
renal injections were performed in adult mice. The trans-
gene cassette consisted of a CMV-promoted EGFP and/or
a luciferase transgene. Transgene expression was evaluated
qualitatively and quantitatively over time. Cellular specifi-
city of expression was evaluated histologically. Delivery of
the vector was well tolerated locally and systemically and
the animals showed no alteration in behavior or general
well-being.
Results
The results from the phase I/II clinical trials showed
improvements in one or more visual function endpoints
for all subjects. There was no evidence of inflammatory
response as a result of surgery or exposure to the vector.
In respect to the animal studies for ciliopathies, the cellu-
lar specificity and efficiency of transduction differed for
each vector/delivery approach. After subretinal injection,
vectors delivered high levels of transgene product to
ciliated photoreceptor cells. In the otocyst, vectors trans-
duced targeted cochlear hair cells efficiently. Following a
trans-ureteral approach, transgene expression in the kid-
ney was visible in the tubule cells of the collecting ducts.
Conclusions
Initial phases for retinal gene therapy have shown safety
and efficacy, which have given rise to the first Phase III
clinical trial for retinal degenerative disease, which is
ongoing. AAV vectors allow efficient transduction of speci-
fic subsets of cells with primary cilia. AAV vectors can effi-
ciently transduce photoreceptors, cochlear hair cells, and
renal tubular epithelial cells, and could be used to develop
treatments for retinal and cochlear degeneration and inher-
ited kidney disease, respectively. These vectors could also
be employed to treat syndromes such as Usher Syndrome,
Bardet-Biedl Syndrome and polycystic kidney disease.
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